Sudeep Pharma IPO: Exciting ₹95 Cr Fresh Issue & OFS Launch

Sudeep Pharma IPO is fully book build issue and total IPO size is ₹null crores. The entire share offering is a fresh issue worth ₹95.00 crores.

The dates for the Sudeep Pharma IPO have not been announced yet. The allotment process is expected to be finalized by [.].

The Sudeep Pharma IPO is scheduled to list on BSE, NSE, with a listing date of [.]. The price band for the Sudeep Pharma IPO has not been announced yet.

Registrar for this IPO is Mufg Intime India Private Limited and lead managers for Sudeep Pharma IPO are Icici Securities Limited, Iifl Capital Services Limited.

Explore more upcoming IPOs in India for comparison and investment planning.

IPO Schedule

IPO Open Date	-
IPO Close Date	-
IPO Allotment Date	-
Refund Initiation	-
Share credit in Demat	-
Listing Date	-

Key Details

Price Band	TBA
Lot Size	TBA
Face Value	₹1 Per Equity Share
Total Issue Size	10,076,492 Shares + ₹95 Crores
Fresh Issue	₹95.00 Crores
OFS Issue	10,076,492 Shares
Issue Type	Fresh Issue and Offer for Sale
Listing At	BSE, NSE

Share Reservation

Investor Category	Shares Offered
QIB	50%
Retail	35%
NII/HNI	15%

About Sudeep Pharma Limited Company

Sudeep Pharma: Powering Industries with Innovation

Sudeep Pharma is a technology-driven manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries. We leverage in-house technologies like encapsulation, spray drying, and blending to drive innovation. With a global presence spanning approximately 100 countries, including key regions like the United States, Europe, and Asia-Pacific, we are committed to contributing to the global healthcare ecosystem.

We are one of the largest producers of food-grade iron phosphate for infant nutrition and one of the largest exporters of mineral ingredients from India. As of December 31, 2024, we have served over 1,100 customers, including Pfizer Inc, Intas Pharmaceuticals Limited, and Danone S.A., and we have built longstanding relationships with marquee customers.

Our business is structured into two verticals: Pharmaceutical, food, and nutrition, focusing on refined, mineral-based single ingredients, and Specialty Ingredients, which produces customized ingredients to improve functionality and bioavailability. We operate three advanced manufacturing facilities in Vadodara, Gujarat, with a combined annual manufacturing capacity of 65,579 MT. Our commitment to R&D and quality certifications underscores our dedication to delivering safe and effective ingredients.

Sudeep Pharma Limited Financial Details

Period Ended	31 Dec 2024	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	656.92	513.87	420.11	345.00
Revenue
Profit After Tax
Net Worth	449.72	356.00	223.29	162.80
Reserves and Surplus	437.75	354.59	221.88	161.40
Total Borrowing	117.19	75.03	82.26	83.71

₹ In Crore

Key Performance Indicator

Basic EPS (in ₹)	Return on Net Worth (RoNW)	Net Asset Value (NAV)	Debt-Equity Ratio	Return on Equity (ROE)	Return on Capital Employed (ROCE)
12.27	37.08%	33.09	0.17	37.40%	41.18%

Offer Objectives

The Offer comprises a Fresh Issue and an Offer for Sale. Selling Shareholders include Sujit Jaysukh Bhayani (up to 3,567,670 Equity Shares), Sujeet Jaysukh Bhayani HUF (up to 5,004,622 Equity Shares), Shanil Sujit Bhayani (up to 750,000 Equity Shares), and Avani Sujit Bhayani (up to 754,200 Equity Shares).

The company plans to utilize the Net Proceeds from the Fresh Issue for capital expenditure of ₹75.814 crore towards procurement of machinery for the production line at Nandesari Facility I, and for general corporate purposes. The amount allocated for general corporate purposes will not exceed 25% of the Gross Proceeds.

A Pre-IPO Placement of specified securities aggregating up to ₹19 crore may be considered. If undertaken, this amount will be reduced from the Fresh Issue, subject to regulatory compliance.

The proposed deployment of Net Proceeds includes ₹75.814 crore in Fiscal 2026 for capital expenditure. The actual deployment is subject to various factors, including market conditions and business requirements. Transactions in Equity Shares by Promoters and Pre-IPO placements (if any), between the Draft Red Herring Prospectus filing date and the Offer closure date, will be reported to the Stock Exchanges within 24 hours.